K. R.

455 total citations
7 papers, 342 citations indexed

About

K. R. is a scholar working on Genetics, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, K. R. has authored 7 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in K. R.'s work include Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). K. R. is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). K. R. collaborates with scholars based in United States, Denmark and United Kingdom. K. R.'s co-authors include Lee Brettman, R Mercier, Barry Mitchell, M. Robert Cooper, Bret Wacker, P. Santabárbara, Edward A. Stadtmauer, Carl E. Freter, Christian H. Geisler and R. Foà and has published in prestigious journals such as Journal of Clinical Oncology, Leukemia and Haematologica.

In The Last Decade

K. R.

5 papers receiving 331 citations

Peers

K. R.
Mary Browning United States
P Travade France
B. Ceglarek Poland
D. Janson United States
Mt Fierro Italy
Jean-Yves Follézou France
R B Slease United States
R. F. Bezares Argentina
M. Hidajat Belgium
A. Lakhani United Kingdom
Mary Browning United States
K. R.
Citations per year, relative to K. R. K. R. (= 1×) peers Mary Browning

Countries citing papers authored by K. R.

Since Specialization
Citations

This map shows the geographic impact of K. R.'s research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. R. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. R. more than expected).

Fields of papers citing papers by K. R.

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. R.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. R.. The network helps show where K. R. may publish in the future.

Co-authorship network of co-authors of K. R.

This figure shows the co-authorship network connecting the top 25 collaborators of K. R.. A scholar is included among the top collaborators of K. R. based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. R.. K. R. is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
2.
Elstrom, Rebecca, Steven L. Allen, K. R., et al.. (2010). Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 96(4). 567–573. 40 indexed citations
3.
Österborg, Anders, R. Foà, R. F. Bezares, et al.. (2009). Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 23(11). 1980–1988. 60 indexed citations
4.
Allen, Steven L., K. R., Rebecca Elstrom, et al.. (2009). Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies. Journal of Clinical Oncology. 27(15_suppl). 8530–8530. 5 indexed citations
5.
Wasil, Tarun, K. R., Emilia Albesiano, et al.. (2005). In B-CLL, time to first treatment is dependant on the IgVH gene mutations and expression of CD38 on leukemic cells. Journal of Clinical Oncology. 23(16_suppl). 6555–6555.
6.
R., K., Carl E. Freter, R Mercier, et al.. (2002). Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine. Journal of Clinical Oncology. 20(18). 3891–3897. 236 indexed citations
7.
R., K., Janet Cuttner, J F Holland, et al.. (1987). Therapeutic Strategies in Acute Myelocytic Leukemia: A Status Report of the Experience of CALGB. Hämatologie und Bluttransfusion. 30. 31–34. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Browning Breakdown of academic impact, for papers by P Travade Breakdown of academic impact, for papers by B. Ceglarek Breakdown of academic impact, for papers by D. Janson Breakdown of academic impact, for papers by Mt Fierro Breakdown of academic impact, for papers by Jean-Yves Follézou Breakdown of academic impact, for papers by R B Slease Breakdown of academic impact, for papers by R. F. Bezares Breakdown of academic impact, for papers by M. Hidajat Breakdown of academic impact, for papers by A. Lakhani
Rankless by CCL
2026